February 2, 2010
NanoBio Awarded Key Patent Covering Vaccine and Anti-infective Product Platforms
December 16, 2009
GSK and NanoBio Announce Licensing Agreement
December 7, 2009
NanoBio to Present Data on its Novel Nanoemulsion-based Vaccine Adjuvant Platform at the World Influenza Congress
December 2, 2009
Novel Intranasal Nanoemulsion Vaccine Adjuvant also Effective by Subcutaneous and Intramuscular Injection
October 15, 2009
NanoBio's Nanoemulsion Kills Drug-Resistant Bacteria Found in Cystic Fibrosis Patients
October 13, 2009
NanoBio and the University of Michigan to Receive $9.3M from the NIH for Nanoemulsion-Based Vaccine Development
September 14, 2009
NanoBio Presents Key Data on the Use of Nanoemulsions to Treat Burn Wound Infections
September 8, 2009
NanoBio's Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection Against Influenza
August 17, 2009
NanoBio to Present Preclinical Data on its Novel, Nanoemulsion-based
Vaccine Adjuvant Platform at the Immunotherapeutics & Vaccine Summit
July 29, 2009
NanoBio to Announce Key Preclinical Data on Nanoemulsions for the Treatment of Acne at American Academy of Dermatology Summer Meeting
July 8, 2009
NanoBio Announces Closing of $22 Million Series B Financing Round Funds will Support Clinical Trials and Ongoing Operations Through Early 2011
May 6, 2009
NanoBio to Announce Key Preclinical Data on Topical Anti-infective Lotions at Society of Investigative Dermatology Meeting
April 23, 2009
NanoBio to Announce Key Immune Response Data for
Influenza at NFID Conference
April 20, 2009
NanoBio Initiates FDA Approved Clinical Trial for Adjuvanted Intranasal Influenza Vaccine
March 2, 2009
NanoBio to Announce Key clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009
January 29, 2009
Nanoemulsion Kills Highly Resistant Bacteria Found in Patients with Cystic Fibrosis
November 13, 2008
NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists
October 28, 2008
Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
October 27, 2008
NanoBio Demonstrates New Topical Approach to Treating Nail Fungus that Circumvents Problems of Current Therapy
October 27, 2008
Nanoemulsion-based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity using Significantly Less Antigen
October 21, 2008
NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008
August 13, 2008
Nasal Hepatitis B Vaccine Elicits Robust Immunity with a Single Dose; Confers a Major Advantage over Traditional Vaccines
July 8, 2008
Daniel B. Dubin, MD Joins NanoBio Corporation’s Board of Directors
June 24, 2008
FierceBiotech Names NanoBio Corporation as One of the “Fierce 15" Biotech Companies of 2008
May 29, 2008
David M. Stout Joins NanoBio Corporation's Board of Directors
March 20, 2008
NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
March 17, 2008
NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
March 11, 2008
NanoBio Founder Named 2008 Distinguished University Innovator
March 06, 2008
NanoBio Corporation Completes $30 Million Funding by Meeting Key Development Milestones
February 26, 2008
Nasal Vaccine for Smallpox Confers High Levels of Immunity without Safety Risks
February 1, 2008
NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
January 30, 2008
New Patent Awarded for Vaccine Adjuvant Technology that Elicits Robust Immunity
January 15, 2008
Stephen Gracon, D.V.M., Joins the NanoBio Team as VP of Regulatory Affairs
October 30, 2007
Joyce Sutcliffe, PhD, Joins the NanoBio Team as Vice President of Research
October 5, 2007
NanoBio Wins 2007 Michigan Innovation Award
September 25, 2007
NanoBio Expands Drug Development Team for its Anti-Infective Products
September 19, 2007
New Topical Therapy Safely Treats Serious Skin Infections without Systemic Side Effects
August 16, 2007
Easy-to-use nasal anthrax vaccine offers strong protection in animal studies
July 17, 2007
Jerald C. Sadoff, MD Joins NanoBio Scientific Advisory Board
July 10, 2007
NanoBio® Corporation Receives $2.4M Award From Michigan's 21st Century Jobs Fund
May 22, 2007
NanoBio® Corporation Announces Positive Phase 1
Clinical Results for Topical Treatment for Onychomycosis
April 3, 2007
NanoBio Corporation Initiates Phase 2 Clinical Trial for the treatment of Onychomycosis
February 15, 2007
NanoBio Corporation Initiates Phase 2b Clinical Trial for Herpes Labialis Treatment
October 11, 2006
NanoBio Corporation Announces Appointment of Dr. Ronald Cresswell to Board of Directors
September 27, 2006
Dr. Robert C. Moellering, Jr. Joins NanoBio Corporation's Board of Directors
August 7, 2006
NanoBio Secures $30 Million Private Equity Financing
February 9, 2006
David Peralta Joins NanoBio as CFO
July 11, 2005
$6.3M Gates Foundation Grant Secured for Development of a NanoStat™ Based Mucosal Vaccine
June 17, 2004
Jay Birnbaum, Ph.D., Joins Science Advisory Board
January 29, 2004
Three New Patents Awarded
December 16, 2003
Dept. of Defense Awards NanoBio $3.2 Million Contract
|
